A Comparative Study on In vitro Anti-cancer and In vivo Anti-angiogenic Effects of TRPC Blockers Pyr-3 and SKF-96365

Basit Öğe Kaydı
dc.authoridOZTURK, A. ALPER/0000-0001-9596-0538
dc.contributor.authorKiyan, Hulya Tuba
dc.contributor.authorUvez, Ayca
dc.contributor.authorErkisa, Merve
dc.contributor.authorIkitimur-Armutak, Elif Ilkay
dc.contributor.authorYilmazer, Nadim
dc.contributor.authorEsener, Osman Behzat Burak
dc.contributor.authorKutucu, Deniz Erol
dc.date.accessioned2024-10-29T17:59:00Z
dc.date.available2024-10-29T17:59:00Z
dc.date.issued2023
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstractIntroduction Angiogenesis is involved in many physiological and pathological conditions including cancer. A number of TRP channels induce angiogenesis, promote cell proliferation or induce apoptosis in several types of human cancers. Therefore, TRP channels may be considered potential pharmacological targets for therapeutic options of disorders caused by insufficient angiogenesis or aberrant vascularization. Aims This study aimed to comparatively investigate in vitro anti-cancer and in vivo anti-angiogenic effects of TRPC blockers Pyr-3 and SKF-96365. Methods For anti-cancer effects, four cancer cell lines (MDA-MB-231, A549, PC-3, and HCT-116) were used. In vivo anti-angiogenic effects were investigated by employing in vivo CAM assay of fertilized hen eggs. Results Pyr-3 affected cell viability in a dose-dependent manner, all concentrations of SKF-96365 significantly reduced cell viability in all cell lines. Pyr-3 and SKF-96365 at concentrations of 2.5 & mu;g/pellet and 50 & mu;g/pellet, respectively inhibited in vivo angiogenesis significantly. Conclusion The concentration of 2.5 & mu;g/pellet caused no irritation, whereas 50 & mu;g/pellet produced some slight irritation. Apart from their anti-cancer effects, our findings indicate that Pyr-3 and SKF-96365 may be promising anti-angiogenic agents for the treatment of angiogenesis-related disorders.
dc.identifier.doi10.2174/1570180820666230110155332
dc.identifier.endpage964
dc.identifier.issn1570-1808
dc.identifier.issn1875-628X
dc.identifier.issue7en_US
dc.identifier.scopus2-s2.0-85159792279
dc.identifier.scopusqualityQ3
dc.identifier.startpage957
dc.identifier.urihttps://doi.org/10.2174/1570180820666230110155332
dc.identifier.urihttps://hdl.handle.net/20.500.11776/14591
dc.identifier.volume20
dc.identifier.wosWOS:001018355100015
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherBentham Science Publ Ltd
dc.relation.ispartofLetters in Drug Design & Discovery
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectPyr-3
dc.subjectSKF-96365
dc.subjectcancer
dc.subjectangiogenesis
dc.subjectin vivo CAM assay
dc.subjectcorpus luteum formation
dc.titleA Comparative Study on In vitro Anti-cancer and In vivo Anti-angiogenic Effects of TRPC Blockers Pyr-3 and SKF-96365
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu